Until recently, GLP-1 weight loss meant a weekly injection. That changed in the past year. The FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025, and approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026. Telehealth ads now pitch the pill as the same result without the needle. The trial data support part of that claim.
The Claim
“GLP-1 pills give you the same weight loss as the shots, just without the needle.”
(Composite representative claim drawn from telehealth and weight-loss clinic marketing.)
Two Very Different Pills
The Wegovy pill is the same peptide as the Wegovy shot. Peptides are broken down in the gut, so the tablet includes an absorption enhancer called SNAC, and even with it only about 1–2% of the dose reaches the bloodstream. That is why the rules are strict: take it on an empty stomach with no more than 4 ounces of water, then wait at least 30 minutes before eating, drinking, or taking other pills. The dose steps up from 1.5 mg through 4 and 9 mg to 25 mg.
Foundayo (orforglipron) is a small molecule, not a peptide. It activates the same GLP-1 receptor but is absorbed like an ordinary pill, so it has no food or water restrictions. It is also cheaper to manufacture at scale than a peptide, which matters for supply.
How Much Weight Do People Lose?
No trial has compared a GLP-1 pill directly with a GLP-1 shot for obesity. The numbers below come from separate placebo-controlled trials with similar designs, so treat the comparison as approximate.
| Drug (trial) | Length | Weight loss vs placebo | Stopped for side effects |
|---|---|---|---|
| Wegovy pill 25 mg (OASIS 4) | 64 weeks | 13.6% vs 2.2% | 7% vs 6% |
| Foundayo, top dose (ATTAIN-1) | 72 weeks | 11.2% vs 2.1% | 10.3% vs 2.7% |
| Wegovy shot 2.4 mg (STEP 1) | 68 weeks | 14.9% vs 2.4% | 7.0% vs 3.1% |
| Zepbound, top dose (SURMOUNT-1) | 72 weeks | 20.9% vs 3.1% | 6.2% vs 2.6% |
The Wegovy pill comes close to the Wegovy shot, which makes sense because it is the same drug. Foundayo produces less weight loss than either semaglutide product, and its top dose had the highest rate of people stopping because of side effects. Zepbound (tirzepatide), which acts on two hormone receptors, remains well ahead of every pill. Gastrointestinal side effects were common across the board: 74% of OASIS 4 participants on the pill reported them, close to the rate seen with the shot.
Switching From a Shot to a Pill
The most practical use for a pill may be maintenance. In Lilly’s ATTAIN-MAINTAIN trial, people who had lost weight on a shot were switched to orforglipron or placebo for 52 weeks. Those coming off Wegovy kept 79.3% of their lost weight on orforglipron, compared with 37.6% on placebo. Those coming off Zepbound kept 74.7%, compared with 49.2%. The trial had no group that stayed on the shot, so it shows the pill is far better than stopping. It does not show the pill is as good as continuing the injection.
Do the Pills Cause Less Hair Loss?
Hair shedding is one of the most common concerns we hear about GLP-1 drugs, and the pills do not avoid it. Reported alopecia rates in the trials:
- Wegovy pill 25 mg (OASIS 4): 6.4% vs 2.0% on placebo
- Oral semaglutide 50 mg (OASIS 1): 7% vs 3%
- Foundayo (ATTAIN-1): 4.1–5.4% vs 2.4%, depending on dose
- Zepbound shot (SURMOUNT-1): 4.9–5.7% vs 0.9%
These rates are similar because the main cause appears to be the weight loss itself. A 2026 systematic review attributes most GLP-1 hair loss to telogen effluvium, a temporary shedding triggered by rapid weight loss and lower calorie and protein intake. It is not tied to whether the drug is injected or swallowed. We cover what to expect in our GLP-1 hair shedding timeline and our Ozempic and hair loss review.
Price and Access
Both companies launched with self-pay pricing aimed at people without insurance coverage. At launch, the Wegovy pill started at $149 a month for the lowest dose and rose to $299 for the 9 mg and 25 mg doses. Foundayo also starts at $149 a month, with higher doses priced higher. Both list a $25 copay for some commercially insured patients. Prices have changed since launch, so check the manufacturer’s current page before you budget.
Watch Out for “Oral Drops” and Sublingual Semaglutide
The approved pills are not the same as compounded semaglutide “drops,” sublingual tablets, or troches sold by some telehealth sites. No published human data show how much semaglutide these products deliver, and a 2026 review in Annals of Pharmacotherapy described their efficacy and safety as “largely unknown.” Given that even the engineered Wegovy tablet absorbs only 1–2% of its dose, there is little reason to expect a compounded drop to work reliably. The FDA has warned telehealth companies not to present compounded GLP-1s as FDA-approved or equivalent to approved drugs. Our compounded GLP-1 review has more background.
What This Means for You
If needles are the barrier, the Wegovy pill gets you close to the Wegovy shot, as long as you can follow the morning routine every day. Foundayo is easier to take but produces somewhat less weight loss. If you want the largest possible effect, the tirzepatide shot still leads. A pill is also a reasonable way to maintain weight loss after a shot, though the evidence for that comes from a single trial. Expect the same nausea and the same risk of temporary shedding with either form, and talk to your prescriber about protein intake during the first months.
Verdict: Partially Supported
The Wegovy pill produces weight loss close to the Wegovy shot, but it requires a strict daily routine. Foundayo is more convenient but less effective, and no pill matches tirzepatide. Side effects, including hair shedding, are similar whether the drug is swallowed or injected. Compounded drops and sublingual products are not equivalent to the approved pills.
References & Further Reading
- Novo Nordisk. (2025, December 22). FDA approves Wegovy pill for chronic weight management. And (2026, January 5). Wegovy pill available nationwide.
- U.S. Food and Drug Administration. (2026, April 1). FDA approves first new molecular entity under National Priority Voucher program.
- Eli Lilly. (2026, April 1). FDA approves Lilly’s Foundayo (orforglipron). And ATTAIN-1 topline results.
- Wharton, S., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine.
- Knop, F. K., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). The Lancet.
- Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine.
- American College of Cardiology. SURMOUNT-1 trial summary.
- ATTAIN-MAINTAIN trial results (orforglipron after Wegovy or Zepbound). PubMed Central.
- Systematic review of hair loss with GLP-1 and related drugs (2026). PubMed Central.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
- Review of compounded GLP-1 formulations (2026). Annals of Pharmacotherapy.
- Marketing or Science. GLP-1 hair shedding timeline, Ozempic and hair loss, and Compounded GLP-1s.